Hypothesis

In aged bone marrow, expanded adipocytes secrete CCL5, which binds CCR5 receptors on osteoprogenitor cells and alters the downstream signaling of erythropoietin (EPO) through its receptor (EpoR). Instead of the canonical STAT5‑mediated survival and osteoblast‑supportive program, CCR5 engagement skews EpoR signaling toward NF‑κB and MAPK pathways, leading to increased secretion of osteoclast‑activating factors (e.g., M‑CSF, RANKL) and suppressed osteoblast differentiation. Concurrently, this altered EpoR signaling in osteoprogenitors reduces the production of niche factors that promote erythroid differentiation, contributing to EPO resistance independent of HSC‑intrinsic defects [2]. Thus, adipocyte‑derived CCL5 creates a paracrine loop that uncouples erythropoietic stimulation from bone preservation, explaining why EPO therapy improves anemia but accelerates trabecular bone loss in the elderly.

Mechanistic Rationale

1. Adipocyte CCL5 up‑regulation – Aging marrow adipocytes increase CCL5 secretion as part of a senescence‑associated secretory phenotype (SASP) [2].
2. CCR5 expression on osteoprogenitors – Osteolineage cells express CCR5, and its activation is known to modulate NF‑κB signaling [5].
3. Signal bias – CCL5‑CCR5 engagement can recruit β‑arrestin pathways that interfere with EpoR‑JAK2‑STAT5 phosphorylation, shifting signaling toward ERK1/2 and p38 MAPK, which drive osteoclastogenic gene expression [3],[4].
4. Effect on niche – Osteoprogenitors under CCR5‑biased signaling produce less SCX and CXCL12, diminishing erythroid support, while up‑regulating M‑CSF and RANKL, promoting osteoclast maturation [5].
5. Outcome – Exogenous EPO therefore expands osteoclast activity via this maladaptive EpoR/CCR5 crosstalk, blunting the expected erythroid boost and worsening bone loss.

Testable Predictions

• Prediction 1: In aged mice, marrow adipocyte CCL5 levels correlate positively with serum TRAP (osteoclast activity) and negatively with bone volume/total volume (BV/TV) after EPO administration [1].
• Prediction 2: Genetic deletion of Ccr5 specifically in osteoprogenitors (using Osx‑Cre;Ccr5^fl/fl) will prevent EPO‑induced trabecular bone loss without impairing EPO‑driven erythropoiesis.
• Prediction 3: Pharmacological blockade of CCR5 (e.g., with maraviroc) in aged mice receiving EPO will reduce osteoclastogenic cytokines (M‑CSF, RANKL) in bone marrow supernatant and preserve bone density, while maintaining or improving hemoglobin response [6],[7].
• Prediction 4: In vitro, osteoprogenitor cultures treated with recombinant CCL5 will show decreased STAT5 phosphorylation and increased NF‑κB p65 nuclear translocation upon EPO stimulation, accompanied by elevated RANKL mRNA.

Falsifiability

If any of the above experiments fail—e.g., Ccr5 deletion does not attenuate bone loss, or CCR5 blockade does not alter osteoclast markers despite confirmed target engagement—the hypothesis would be refuted, suggesting that adipocyte‑derived CCL5 is not the primary mediator of EPO‑induced bone dysfunction.

Broader Implications

Confirming this mechanism would reveal a druggable node (CCR5) that could decouple the anabolic benefits of EPO from its catabolic bone side‑effects, offering a strategy to treat unexplained anemia in the elderly while preserving skeletal integrity.